Elanco Animal Health (ELAN) News Today

Elanco Animal Health Incorporated (ELAN) saw its stock price increase after reporting stronger-than-expected Q2 results, raising guidance and receiving an analyst upgrade on innovation-driven growth.

• Positive Sentiment: Q2 earnings per share of $0.26 topped the $0.20 consensus, while revenue of $1.24 billion exceeded the $1.19 billion estimate, reflecting 4.8% year-over-year growth. Elanco Q2 Beats Estimates
• Positive Sentiment: The company raised its full-year 2025 outlook, boosting revenue guidance to $4.57 billion–$4.62 billion, adjusted EPS to $0.85–$0.91, innovation revenue target by $60 million to $720 million–$800 million, and improved its year-end net leverage ratio target. Q2 Results and Raised Guide
• Positive Sentiment: Analyst rating upgraded to Buy with a $20 fair-value target, highlighting strong innovation products like Zenrelia and improved operational execution. Buy Rating Initiated
• Positive Sentiment: Elanco updated its fiscal 2025 guidance, raising expected EPS to $0.850–$0.910 (versus consensus $0.840) and revenue to about $4.6 billion (above the $4.5 billion consensus).
• Neutral Sentiment: Management hosted its Q2 2025 earnings call transcript, detailing strategic priorities and operational outlook. Earnings Call Transcript
• Neutral Sentiment: Third-quarter guidance for Q3 2025 was set at $0.120–$0.160 EPS and approximately $1.1 billion in revenue, roughly in line with Street forecasts.
• Neutral Sentiment: Zacks highlighted key performance metrics versus Wall Street estimates for the quarter, providing context for its operating performance. Key Metrics Analysis
• Neutral Sentiment: Earlier previews of Q2 performance and earnings previews were published, reminding investors of the expected release timing without new material updates. Earnings Preview